Received: Feb 20, 2018 at 7:15 PM Subject: Consider a twice-weekly therapy that keeps things simple for you From: CSL Behring Team
Received: Oct 4, 2018 at 12:01 PM Subject: 1 alternative to Helixate® FS: Novoeight® (Antihemophilic Factor [Recombinant]). From: Novo Nordisk
From: ACADIA Pharmaceuticals Inc. Sent on: Jan 21, 2019 Subject line: You signed up to learn more. We’re happy to help Preheader: Please see Important Safety Information including Boxed WARNING at the bottom of this email.
From: Endo Info Sent on: Jan 8, 2019 Subject line: Pushing through painful periods? Preheader: You don’t have to grin and bear it! Ask your doctor if it could be endometriosis. Resent on Jan 15, 2019 after not opening an email: Subject line: Hey [First Name], got painful periods? Pre-header: Ask your doctor if it could be endometriosis.
Subject line: Commercial Copay Assistance Sent on: 8/23/2018 at 9 AM From: Managing LGS Pre-header: Learn about the updates to our Commercial Copay Assistance Program
Subject line: 3 important considerations regarding rFIX treatments Sent on: Aug 16, 2018 at 7AM From: Novo Nordisk Pre-header: Providing more for your patients with hemophilia B.
Received: June 20, 2018 at 7:02 AM Subject: Meet Vaughn, who lives with hemophilia A From: Novo Nordisk
Email 1, subject line 1: A new treatment option for your patients Sent on: Nov 11, 2017 at 10am EST Same email, resent: Email 1, subject line 2: FDA Approved for 2018: Rebinyn® (Coagulation Factor IX [Recombinant], GlycoPEGylated) Sent On: Jan 21, 2018 at 4pm EST Email 2 subject line: Now available: Rebinyn® (Coagulation Factor IX [Recombinant], GlycoPEGylated) Continue reading
Subject line: Ready to up your endometriosis IQ? Received on: March 27, 2018 at 9:30am From: SpeakENDO